What Naltrexone Accord Treats: Main Uses and Benefits

The primary role of Naltrexone Accord is to serve as an integral part of a comprehensive program for patients seeking recovery from substance use disorders. It may assist patients in supporting their abstinence goals and contribute to reducing the risk of relapse. It is commonly used to manage two main condition categories: Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).

Symptom Management and Recovery Support

Naltrexone Accord is utilized as a pharmacological support in the treatment of AUD, and may assist in lessening the compulsive urges and cravings for alcohol, which are symptoms that create noticeable functional strain. The primary therapeutic benefit may contribute to easing the burden of heavy drinking and supports efforts to reduce the overall amount of alcohol consumed, providing supportive relief. In the clinical setting of OUD, this medication is relevant for patients who are fully abstinent and provides supportive therapeutic benefit by addressing the symptoms related to the euphoric and reinforcing effects of opioids. This assists with maintaining functional stability and may assist the patient in sustaining a commitment to long-term recovery.

“Its application may assist patients with maintaining stability and contributes to supporting general well-being during symptomatic phases.”

It is considered relevant within a comprehensive treatment plan that includes counseling and behavioral therapies.

---

Quick Fact: Support for Compulsive Cravings

Property	Description
Primary Use Focus	Management of cravings and compulsion to use substances.
Conditions Treated	Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).
Patient Benefit	May assist with sustaining abstinence and supports efforts to reduce heavy drinking.
Clinical Context	Adjunctive part of a comprehensive recovery program.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Eligibility Map: Who can and cannot use Naltrexone Accord — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Use is established for adults who are confirmed to be opioid-free, typically after achieving a minimum of 7 to 10 days of abstinence from short-acting opioids.

Populations for whom use is contraindicated: The medicine is strictly contraindicated in patients currently receiving opioid analgesics, those with physiological opioid dependence, or those in acute opioid withdrawal. It is also contraindicated in any individual with a positive opioid screen, who fails the naloxone challenge test, or who has a known hypersensitivity to the drug. Furthermore, use is prohibited in patients with acute hepatitis or liver failure.

Age-related eligibility rules: Safety and efficacy are not established in children and adolescents under 18 years of age, and use is not recommended in this pediatric population. Use in geriatric patients is not adequately studied, and data are considered insufficient.

Condition-specific eligibility rules: Use requires caution and monitoring in patients with pre-existing hepatic impairment or renal impairment.

Pregnancy and lactation eligibility status (if explicitly documented): Use during pregnancy is restricted to cases where the potential benefit justifies the unknown risk. Use while breastfeeding is not recommended due to a lack of data on infant risk.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute contraindications apply to opioid-dependent status and acute liver conditions. Use is classified as not established or not recommended for pediatric, geriatric, and breastfeeding populations.

Eligibility-context constraints (as defined in official documents): Treatment initiation is constrained by the mandatory requirement for an opioid-free state to avoid precipitated withdrawal.

Official eligibility statements: Eligibility is restricted to adults who can achieve an opioid-free status. Use is contraindicated in patients with acute liver conditions or current opioid dependence. Pediatric and geriatric uses are not recommended due to insufficient data.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use the medicine through strict exclusions related to opioid use and underlying organ health. The core eligibility constraint is the mandatory requirement for the patient to be opioid-free before initiation. Restrictions also apply to age groups and physiological states where safety data are not established.

Interactions with other medicines and products

The interaction profile for Naltrexone Accord focuses primarily on pharmacodynamic effects driven by its classification as a pure opioid antagonist, alongside necessary precautions regarding clearance and additive central nervous system (CNS) effects, as documented in official regulatory sources.

Formal Interaction Classifications

Interaction Type	Interacting Substance/Class	Regulatory Restriction
Pharmacodynamic Antagonism	Opioid Analgesics and Opioid-Containing Medicines	Contraindicated (Risk of acute withdrawal syndrome or blockade of therapeutic effect)
Additive CNS Effects	Sedative Agents (e.g., Thioridazine, Benzodiazepines)	Use with Caution (Risk of increased lethargy and somnolence)

Clearance and Pharmacokinetic Notes

Co-administration with opioid analgesics and opioid-containing cough or anti-diarrheal medicines is strictly prohibited according to regulatory labels. The drug is considered unlikely to affect the metabolism of other co-administered medicinal products because Naltrexone and its primary metabolite, 6-beta-naltrexol, are not significantly metabolized by the human CYP450 enzyme system.

Exposure-related caution is mandated for specific patient populations. Use is officially contraindicated in patients with severe renal or acute hepatic impairment, as reduced clearance can increase systemic drug and metabolite levels. The official prescribing information states that there are no known interactions with food, drink, or alcohol.

How Naltrexone Accord works

Naltrexone Accord's mechanism of action is defined by its role as a pure opioid antagonist acting within the central nervous system. The drug engages in competitive binding with high affinity primarily at the mu (mu)-opioid receptors. By occupying these receptor sites, Naltrexone Accord prevents the binding and subsequent activation of opioid agonists, including both endogenous signaling molecules (e.g., endorphins) and exogenous substances. This interaction initiates a signaling suppression sequence that results in the suppression of excessive signaling within the reward pathways.

This receptor blockade structurally alters the activity of the Endogenous Opioid System (EOS), a key system regulating reward pathway dynamics. The antagonist activity is sustained by the drug’s principal active metabolite, 6-beta-naltrexol, which also functions as an opioid antagonist with a longer biological half-life than the parent compound. This sustained antagonism ensures continuous interference with the opioid signaling pathway, contributing to the persistent nature of the drug's biological activity and pathway modulation.

Administration Scope

Feature	Detail
Route of administration	The medicine is administered via the oral route as a film-coated tablet.
Dosing schedule	The standard maintenance dose for both approved uses is 50 mg once daily. An alternative regimen totals 350 mg per week, divided over three days (e.g., 100 mg, 100 mg, 150 mg), with no single daily dose exceeding 150 mg.
Timing in relation to meals (if applicable)	The tablet may be taken with or without food. Taking the dose with or after a meal is an option to help mitigate potential gastrointestinal upset.
Preparation requirements (if applicable)	The 50 mg tablet may be divided to achieve the 25 mg starting dose required for Opioid Use Disorder (OUD) induction.
Age-group administration rules	Use in pediatric patients (under 18) is generally not established or recommended.
Special procedural conditions	Administration requires the patient to be opioid-free for a minimum of 7 to 10 days prior to the first dose; this prerequisite is often verified by procedural testing.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral (ingestion).
Frequency pattern	Once daily (standard) or thrice-weekly (compliance-based).
Context of use	Clinical protocols define specific daily or weekly schedules for patient adherence.
Use-context constraints	Strict prerequisites concerning the patient's opioid abstinence status and restrictions on use in cases of severe renal or acute hepatic failure.

---

Resulting Procedural Structure

Official step sequence:

• Establish Opioid Abstinence: Confirmation is required that the patient has been opioid-free for the mandatory 7 to 10-day period.
• Initiate Dosing (OUD): Administer the reduced 25 mg starting dose orally once daily.
• Establish Maintenance Dosing: Escalate the oral dose to the standard 50 mg once daily after tolerance is confirmed.
• Continue Administration: Maintain the 50 mg dose once daily (or follow the thrice-weekly schedule) as part of a long-term treatment plan.

---

Connection to the overall use protocol (2–4 sentences):

The official administration guidelines establish a structured sequence that governs the initiation and maintenance of treatment. This protocol begins with the prerequisite of confirmed opioid abstinence, which must precede any dosing. Once initiated, the guidelines stipulate precise, standardized daily or weekly dosage amounts and the oral route of administration, structuring the proper, consistent use of the medicine.

Clinical Research Summary

The clinical evidence for naltrexone primarily focuses on its role as an adjunct in the comprehensive treatment of Alcohol Dependence and Opioid Dependence in detoxified patients. Its therapeutic use is supported by multiple randomized controlled trials and systematic reviews, which assess outcomes such as rates of heavy drinking, time to relapse, and retention in treatment programs.

---

Evidence in Alcohol Dependence

Studies suggest that naltrexone may be associated with beneficial effects in reducing patterns of excessive alcohol consumption. Research observations have indicated a potential increase in the time to first relapse to heavy drinking and a reduction in the overall quantity of alcohol consumed during drinking episodes, compared to placebo. However, the degree of benefit observed across various populations has been reported as modest and can be influenced by factors such as patient genotype and adherence to the prescribed regimen. The medication is typically considered part of a structured psychosocial treatment program.

---

Evidence in Opioid Dependence

In the context of opioid use disorder, naltrexone acts as a blockade agent and is generally indicated for patients who have completed detoxification and are opioid-free. Clinical data, including randomized trials, have demonstrated that naltrexone may be associated with an increased likelihood of maintaining opioid abstinence and longer retention in treatment programs when compared to non-pharmacological interventions. The drug's efficacy relies heavily on consistent use to maintain the blockade of opioid receptors. Research highlights the critical safety consideration that a loss of opioid tolerance occurs during treatment, increasing the risk of overdose if high doses of opioids are used post-cessation.

Common questions about Naltrexone Accord (FAQ)

Q: Can Naltrexone Accord cause trouble sleeping or vivid dreams?

Official documents state that insomnia (difficulty sleeping) is listed as a Very Common side effect. Reports from patients also mention the occurrence of abnormal dreams in some cases, although this is a less frequent observation.

Q: How long does it typically take to start noticing any effect from Naltrexone Accord?

The medicine is rapidly absorbed into the body after it is swallowed. The drug's activity is then sustained by two active forms, the parent compound and an active metabolite, which have elimination half-lives of approximately 4 hours and 13 hours respectively. This pharmacological data suggests the drug is available to act shortly after ingestion, providing sustained duration of the receptor blockade.

Q: What is the duration of action for Naltrexone Accord after taking a dose?

The sustained action of the medicine is supported by two active components that remain in the body. The Naltrexone compound itself has an elimination half-life of about 4 hours. Its primary active metabolite, 6-beta-naltrexol, has a longer half-life of about 13 hours, ensuring continuous opioid receptor antagonism.

Q: Are there any known interactions between Naltrexone Accord and common antidepressant or anti-anxiety medications?

Official information indicates that anxiety and depression may occur as side effects of the medicine itself. Caution is advised when the medicine is used with other sedative agents, such as certain anti-anxiety drugs, as this may increase the risk of drowsiness. Specific advice on non-sedative antidepressants should be sought from a healthcare provider.

Q: How is Naltrexone Accord classified in terms of safety and controlled substances?

Naltrexone Accord is chemically classified as a Pure Opioid Antagonist, meaning it blocks the activity of opioids. According to the U.S. Drug Enforcement Agency (DEA), the oral form of this medicine is not classified as a controlled substance.

Q: Is it normal to feel less motivated or have mood changes on Naltrexone Accord?

Official documents list mood-related side effects including anxiety, nervousness, and irritability as common occurrences. Depression is also listed as a common side effect. Less frequently reported effects include mood swings and abnormal thinking.

Q: What is known about the research regarding Naltrexone Accord and specific patient subgroups?

Clinical studies that support the use of Naltrexone Accord primarily focused on adult populations with alcohol or opioid dependence. Official research notes indicate that the degree of benefit observed can be influenced by certain patient factors, such as genotype and adherence to the prescribed regimen.

Q: Can Naltrexone Accord affect driving or the ability to perform tasks that require focus?

Side effects such as somnolence (drowsiness) and dizziness are listed as Common in regulatory documents. Regulatory notes indicate that the potential for these effects to impair the ability to drive or operate complex machinery is a safety consideration.

Q: What is the maximum amount of time Naltrexone Accord can be safely used according to official sources?

Official regulatory guidelines do not establish a specific maximum duration for the treatment. The guidelines reflect that longer-term use is possible as part of a patient's treatment plan.

Q: Is there any evidence that Naltrexone Accord can affect body weight?

Changes in body weight can be associated with side effects of the medicine. Official reports mention that a loss of appetite may occur due to common gastrointestinal upset. Increased appetite and weight gain have also been reported in rare cases, though these are not listed as frequent adverse events.

Q: What happens if a person forgets to take a dose of Naltrexone Accord?

Official regulatory patient information typically describes the protocol for a missed dose as taking the next scheduled dose at the usual time, without taking two doses together.

Q: Does Naltrexone Accord interact with common over-the-counter pain relievers like ibuprofen?

Caution is advised when this medicine is used alongside other medications that can also affect liver function, such as the over-the-counter pain reliever ibuprofen. Regulatory documents indicate that combining these types of medicines may increase the risk of liver problems.

Q: What is the general information about combining Naltrexone Accord with cold or allergy medicines?

Regulatory documents state that the medicine is contraindicated with all products that contain opioids, which may include certain cough syrups and anti-diarrheal medicines. Non-opioid cold or allergy medicines are not formally listed as a contraindication in official sources.

Q: What is the difference between Naltrexone Accord and the extended-release injection form?

Naltrexone Accord is the oral tablet form, which is typically taken once daily. There is also an extended-release injection form available that is administered once a month. The injection is described as an alternative that may be used for patients who have adherence concerns with the daily oral regimen.

Q: Does Naltrexone Accord require any specific blood tests for monitoring during treatment?

Official guidelines reflect the documented risk of liver injury (hepatotoxicity) by noting that monitoring liver function through blood tests (Liver Function Tests) is typically performed before starting and at periodic intervals during treatment.

Q: What are the official guidelines regarding discontinuing Naltrexone Accord?

Regulatory documents highlight a critical safety consideration when the medicine is discontinued. After cessation, the patient's tolerance to opioids is reduced, which significantly increases the risk of a potentially fatal opioid overdose if opioids are subsequently used.

Q: What do official regulatory documents say about the risks of stopping Naltrexone Accord suddenly?

The primary risk officially highlighted regarding the cessation of the medicine is the immediate loss of the patient's opioid tolerance. This loss of tolerance increases the risk of a potentially fatal opioid overdose if opioids are then used in the same amount as before treatment.

Q: Are there reports of changes in appetite while taking Naltrexone Accord?

Official reports mention that side effects can include a loss of appetite due to common gastrointestinal upset. Increased appetite has also been reported in rare cases, though this is not a frequent adverse event.

Q: How does Naltrexone Accord interact with cannabis or CBD products?

Caution is officially advised when Naltrexone Accord is used with products containing cannabidiol (CBD). This combination is noted in some regulatory documents as potentially increasing the risk of liver problems.

Storage and Disposal of Naltrexone Accord

Naltrexone Accord film-coated tablets must be stored at a temperature no higher than 25 C (77 F), with acceptable excursions up to 30 C (86 F). The medicine must be kept in its original package and a tight container to ensure protection from moisture and maintain the labeled 3-year stability. The product must be stored out of the sight and reach of children at all times.

Disposal

It is mandatory to dispose of unused or expired Naltrexone Accord according to local requirements. Do not throw away the medicine via wastewater or household waste. Consult with a pharmacist regarding appropriate methods for discarding the product to ensure proper pharmaceutical waste handling.